ExeVir announces first subjects dosed Phase 1 clinical study of potent COVID-19 neutralizing antibody

  • Major milestone in development of “pan-coronavirus” nanobodies
  • Now evaluating clinical safety and pharmacokinetics of XVR011, a potent COVID-19 neutralizing antibody – also against Delta variant

Belgium, 18 August 2021: ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH